T. Hattori

Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy

K. Ohta, Y. Tomiyama, K. Miyamura, 2019, International Journal of Hematology.

Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia

H. Nomura, T. Kawaguchi, M. Sata, 2019, Experimental and therapeutic medicine.

Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study

T. Kawaguchi, M. Sata, A. Komori, 2012, Journal of Gastroenterology.

Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study

Y. Miyakawa, Y. Ikeda, Y. Kanakura, 2013, International Journal of Hematology.

A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia

Y. Miyakawa, Y. Ikeda, Y. Kanakura, 2012, Journal of thrombosis and haemostasis : JTH.